What is Jinhe Biotechnology CO., LTD.'s (002688.SZ) StockRank?

MoatMap's StockRank for Jinhe Biotechnology CO., LTD. (002688.SZ) is 39/100, with a Hold signal. This is a composite score combining Quality (45), Value (40), and Momentum (45) factor ranks across MoatMap's 20,000+ stock universe.

Does Jinhe Biotechnology CO., LTD. have an economic moat?

Jinhe Biotechnology CO., LTD. (002688.SZ) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Jinhe Biotechnology CO., LTD. a buy, hold, or sell?

MoatMap's current signal for Jinhe Biotechnology CO., LTD. (002688.SZ) is Hold, based on a StockRank of 39/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Jinhe Biotechnology CO., LTD. in?

Jinhe Biotechnology CO., LTD. (002688.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

002688.SZ

HOLDREMOVE

Jinhe Biotechnology CO., LTD. · Healthcare · China · $628M · Avg Vol: $9M/d

StockRank

P/E (TTM)

100.2x

ROE

0.0%

D/E

1.1x

Dividend %

2.0%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Jinhe Biotechnology focuses on veterinary drugs and additives. It lacks the high-value regulatory moats and pricing power of human-grade CDMOs, failing to align with our CDMO Pricing Power Cycle theme.

COMPANY DESCRIPTION

Jinhe Biotechnology is the world's largest manufacturer of chlortetracycline (CTC), a critical feed additive and veterinary antibiotic. The company commands a dominant global market share, supported by low-cost fermentation capabilities and stringent international quality certifications. It is a highly integrated animal health leader expanding its portfolio into veterinary vaccines and environmental protection services.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	314M	321M	350M	425M	10.7%
EPS	0.01	0.02	0.02	0.01	-28.6%
Shares	780M	780M	772M	772M	-1.1%
Debt	237M	340M	343M	343M	13.1%
Equity	328M	332M	332M	329M	0.1%
Op CF	18M	29M	74M	69M	55.6%
Inv CF	-57M	-79M	-55M	-46M	—
Fin CF	22M	61M	-6M	-18M	—

PRICE (1M)-16.3%

SMA 50SMA 200

$0.74

RSI (14)

42.7

52W High

$1.17

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

3.4%52.0

ROE

0.0%45.1

GP/Assets

17.7%41.8

Op. Margin

14.0%73.3

FCF/Assets

-1.2%46.2

Piotroski

—83.5

Int. Cover

1.5x43.5

D/E Ratio

1.10x13.2

Current Ratio

1.30x18.4

Value

P/E (TTM)

100.2x9.1

EV/EBITDA

10.6x40.3

P/FCF

—N/A

P/B

1.7x61.7

P/S

1.3x79.4

Div Yield

2.0%50.6

Momentum

52W High %

64%46.7

RS 6M

-23%51.2

SMA 50/200

0.91x38.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

22%64.2

FUNDAMENTALS

Market Cap

$628M

P/E (Forward)

16.7x

Gross Margin

32.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 002688.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
002688.SZ	Jinhe Biotechnology CO., LTD.(you)	$628M	39	HOLD
301277.SZ	Newland Pharmaceutical Co., Ltd.	$574M	34	SELL
300194.SZ	Fuan Pharmaceutical (Group) Co., Ltd.	$672M	43	HOLD
300158.SZ	Shanxi Zhendong Pharmaceutical Co.,Ltd	$738M	34	SELL
002728.SZ	Teyi Pharmaceutical Group Co.,Ltd	$671M	32	SELL
688247.SS	Sinotherapeutics Inc.	$571M	33	SELL
600488.SS	Tianjin Tianyao Pharmaceuticals Co., Ltd.	$894M	40	HOLD
002793.SZ	Luoxin Pharmaceuticals Group Stock Co., Ltd.	$690M	31	SELL
600829.SS	HPGC Renmintongtai Pharmaceutical Corporation	$746M	46	HOLD
300485.SZ	Beijing Science Sun Pharmaceutical Co., Ltd.	$634M	27	SELL

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.1%

Jinhe Biotechnology CO., LTD. (002688.SZ) — Stock Score Summary

Jinhe Biotechnology CO., LTD. (002688.SZ) has a MoatMap StockRank of 39/100 based on Quality (45/100), Value (40/100), and Momentum (45/100) factor scores. The current signal is HOLD. Jinhe Biotechnology focuses on veterinary drugs and additives. It lacks the high-value regulatory moats and pricing power of human-grade CDMOs, failing to align with our CDMO Pricing Power Cycle theme.

Key Financial Metrics

Price	$0.74
Market Cap	$628M
P/E (TTM)	100.20
P/E (Forward)	16.70
Price/Book	1.69
Return on Equity	0.0%
Return on Invested Capital	3.4%
Debt/Equity	109.57
Gross Margin	32.6%
Operating Margin	14.0%
Revenue Growth	18.7%
Dividend Yield	2.0%
Free Cash Flow	$-1M

Jinhe Biotechnology CO., LTD. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Jinhe Biotechnology CO., LTD.’s (002688.SZ) StockRank?: MoatMap’s StockRank for Jinhe Biotechnology CO., LTD. (002688.SZ) is 39/100, with a Hold signal. It is a composite of Quality (45), Value (40), and Momentum (45) factor ranks across MoatMap’s 20,000+ stock universe.
Does Jinhe Biotechnology CO., LTD. have an economic moat?: Jinhe Biotechnology CO., LTD. (002688.SZ) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Jinhe Biotechnology CO., LTD. a buy, hold, or sell?: MoatMap’s current signal for Jinhe Biotechnology CO., LTD. (002688.SZ) is Hold, based on a StockRank of 39/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Jinhe Biotechnology CO., LTD. in?: Jinhe Biotechnology CO., LTD. (002688.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).